Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”

On December 9-10, 2023, the "Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit" was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai "Liver" Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center, and the Long Triangle Representative Office of the China Association of Non-Public Medical Institutions. At the conference, Dr.Xiufeng Liu from the Medical Area of the Qinhuai Hospital of the Eastern Theater General Hospital of the People's Liberation Army provided a detailed interpretation of the "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma," which was newly issued in China. This journal has invited Dr.Xiufeng Liu to conduct an in-depth interview to introduce the consensus's recommendations regarding first-line and subsequent-line treatment options for liver cancer immunotherapy, as well as the assessment of treatment efficacy and other hot topics. The following content summarizes these insights for readers.
Potentially Underestimated! Recent Advances in Screening, Treatment, and Prevention of HBV Combined with HDV Infection

Potentially Underestimated! Recent Advances in Screening, Treatment, and Prevention of HBV Combined with HDV Infection

Hepatitis D virus (HDV) is a defective virus that relies on hepatitis B virus (HBV) to produce infectious particles for transmission. The combined infection of both is considered one of the most severe forms of chronic viral hepatitis, posing a significant threat to human health. At the 9th "Silk Road Hepatitis Forum," Dr. Xiaozhong Wang, Director of the Hepatology Department at the Xinjiang Uyghur Autonomous Region Traditional Chinese Medicine Hospital, was invited to present the latest research developments in screening, treatment, and prevention of HBV combined with HDV infection, providing essential insights for clinical management. "International Digest" has invited Dr. Xiaozhong Wang and Dr. Liu Yunxiao to share the highlights of the report.

Unresolved Issues in Pediatric Hepatitis B Treatment Guidelines

China is a high-incidence country for hepatitis B virus (HBV), with mother-to-child transmission being a significant route of HBV infection in children. If infected with HBV, 15% to 25% of children may develop into chronic carriers, posing risks of liver cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of the disease and taking timely and effective treatment measures are of great practical significance. From November 17-19, 2023, the "15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference" was grandly held in Chongqing. It was hosted by the Chinese Medical Journal Company Ltd., organized by the Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis. At the conference, Dr. Junliang Fu of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital sparked intense interest with his thematic discussion on hot issues in pediatric HBV clinical treatment. We are honored to have Dr. Junliang Fu for an in-depth interview, the contents of which are compiled here for our readers.

Discovery and Verification of HBV Auxiliary Receptor NRP1

Hepatitis B Virus (HBV) infection is one of the main causes of liver diseases, affecting approximately 292 million people worldwide who are chronic carriers of HBV, leading to severe conditions like liver cirrhosis and primary liver cancer. The infection process of HBV relies on the binding of the viral envelope proteins to receptors on the cell surface. Therefore, interfering with the binding of the viral envelope proteins and receptors can be an effective antiviral strategy. During the 15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference, held in Chongqing from November 17-19, 2023, and organized by the Chinese Medical Journal Company Ltd., Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis, Dr. Ailong Huang, President of Chongqing Medical University, shared his team's latest research findings on how HBV depends on various receptors and auxiliary receptors to infect cells. This research provides new insights into the mechanism of HBV invasion and the development of novel drugs to block HBV infection.
Dr. Franco Cavalli: Highlights of  ICML 2023 & the Emerging Significance of China in Lymphoma Research

Dr. Franco Cavalli: Highlights of  ICML 2023 & the Emerging Significance of China in Lymphoma Research

From June 13-17, 2023, the biennial international lymphoma academic event - the 17th International Conference on Malignant Lymphoma (ICML) was held in Lugano. As the world's largest international conference on malignant lymphoma, ICML attracts widespread attention from lymphoma experts and scholars both domestically and abroad. In our interview with the conference chair, Dr. Franco Cavalli, he highlighted the main aspects of the ICML conference, discussed the significance of the joint session between the Union of Chinese Clinical Oncology Lymphoma Alliance (UCLI) and ICML, and provided insights into the future collaboration between the International Extranodal Lymphoma Study Group (IELSG) and UCLI.
The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

"The Hepatology Digest -Liver Vascular Disease Column" is an academic section jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater General Hospital, at the invitation of the Hepatology Digest editorial team. It regularly collects and discusses the latest research in the field of liver vascular diseases. Every two weeks, on Wednesdays, it features an in-depth discussion of a significant publication, aiming to enlighten readers about the rationale behind these findings and inspire clinical research and practical application.